The 9 analysts offering 12-month price forecasts for Revance Therapeutics Inc have a median target of 37.00, with a high estimate of 55.00 and a low estimate of 33.00. The median estimate represents a +24.54% increase from the last price of 29.71.
The current consensus among 10 polled investment analysts is to Buy stock in Revance Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.97
Reporting Date Nov 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.